FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409125979> ?p ?o ?g. }

• W2409125979 endingPage "736" @default.
• W2409125979 startingPage "724" @default.
• W2409125979 abstract "Abstract Multiple myeloma is basically an incurable cancer. Most patients respond initially to chemotherapy with reduction in bone marrow (BM) plasma cells and monoclonal Ig levels, but the disease nearly always recurs and becomes refractory to therapy. The objective of this study was to characterize the expression of the multidrug transport pump, P- glycoprotein 170 (P-gp), in myeloma. The great majority of B cells from peripheral blood mononuclear cells (PBMCs) in myeloma express P-gp, detected by the monoclonal antibody MRK-16. P-gp+ blood B cells exhibit extensive DNA hyperdiploidy, suggesting replicative abnormality characteristic of malignant growth. We speculate these represent a stem cell population in myeloma. The proportion of B cells expressing P-gp was comparable among untreated myeloma patients and those treated with chemotherapy, biologic response modifiers, or off treatment. Among BM cells, P-gp was absent or low in untreated myeloma patients but was expressed at high levels on BM cells from patients previously treated with chemotherapy. For untreated patients the majority of B/plasma cells expressing P-gp are located in PBMCs, not the BM cells. Flow cytometric analysis of rhodamine 123 dye efflux indicated a functional P-gp that was efficiently blocked by verapamil or cyclosporin A (CsA). Both the CD11bhi CD19+ B cells and the T cells in myeloma PBMCs had active CsA-inhibited dye efflux, but monocytes lacked the ability to efflux dye. Nearly all CD38hi plasma cells from myeloma BM cells retained dye, indicating their lack of a functional transport pump. Thus, PBMC B cells may be the predominant set of drug-resistant tumor cells. Myeloma PBMC B cells were cultured with Adriamycin with or without CsA and drug toxicity evaluated by the induction of apoptosis, using flow cytometry to quantitate DNA disruption. No apoptosis was detectable at 0.01 microgram/mL adriamycin, the in vivo steady-state level, with or without CsA. With 0.1 microgram adriamycin, no apoptosis was detectable in the absence of CsA, but with CsA, 66% of B cells initiated DNA disruption, whereas most T cells were spared. This work suggests that currently used drug dosages are too low to effect P-gp+ B- cell death, even in the presence of CsA. We suggest that blood B cells comprise a highly drug-resistant subset of the myeloma B lineage that escapes conventional chemotherapy and may underlie the almost uniform fatal relapse in myeloma patients." @default.
• W2409125979 created "2016-06-24" @default.
• W2409125979 creator A5058237113 @default.
• W2409125979 creator A5073964632 @default.
• W2409125979 date "1994-02-01" @default.
• W2409125979 modified "2023-10-17" @default.
• W2409125979 title "Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma" @default.
• W2409125979 cites W1481699366 @default.
• W2409125979 cites W1485176492 @default.
• W2409125979 cites W1599388734 @default.
• W2409125979 cites W1651390879 @default.
• W2409125979 cites W1754065147 @default.
• W2409125979 cites W179300038 @default.
• W2409125979 cites W187389121 @default.
• W2409125979 cites W1965770034 @default.
• W2409125979 cites W1973996352 @default.
• W2409125979 cites W1976017022 @default.
• W2409125979 cites W1979129905 @default.
• W2409125979 cites W1996845076 @default.
• W2409125979 cites W2004136640 @default.
• W2409125979 cites W2005877531 @default.
• W2409125979 cites W2025044697 @default.
• W2409125979 cites W2025392360 @default.
• W2409125979 cites W2025442473 @default.
• W2409125979 cites W2027947014 @default.
• W2409125979 cites W2028159684 @default.
• W2409125979 cites W2033319174 @default.
• W2409125979 cites W2038933446 @default.
• W2409125979 cites W2040342801 @default.
• W2409125979 cites W2041209857 @default.
• W2409125979 cites W2051143903 @default.
• W2409125979 cites W2057993986 @default.
• W2409125979 cites W2060351323 @default.
• W2409125979 cites W2061161155 @default.
• W2409125979 cites W2072035010 @default.
• W2409125979 cites W2074053978 @default.
• W2409125979 cites W2077317989 @default.
• W2409125979 cites W2078357711 @default.
• W2409125979 cites W2079867467 @default.
• W2409125979 cites W2083521623 @default.
• W2409125979 cites W2083988731 @default.
• W2409125979 cites W2087869106 @default.
• W2409125979 cites W2088419541 @default.
• W2409125979 cites W2121547160 @default.
• W2409125979 cites W2125112635 @default.
• W2409125979 cites W2132084215 @default.
• W2409125979 cites W2138993111 @default.
• W2409125979 cites W2150115756 @default.
• W2409125979 cites W2150946292 @default.
• W2409125979 cites W2158881465 @default.
• W2409125979 cites W2160070601 @default.
• W2409125979 cites W2167180212 @default.
• W2409125979 cites W2264155967 @default.
• W2409125979 cites W2288545761 @default.
• W2409125979 cites W2301279425 @default.
• W2409125979 cites W2324375318 @default.
• W2409125979 cites W2397577365 @default.
• W2409125979 cites W2404356933 @default.
• W2409125979 cites W2408688530 @default.
• W2409125979 cites W2413331114 @default.
• W2409125979 cites W2413395556 @default.
• W2409125979 cites W2417273507 @default.
• W2409125979 cites W2464283931 @default.
• W2409125979 cites W2468000500 @default.
• W2409125979 cites W25060515 @default.
• W2409125979 cites W25713858 @default.
• W2409125979 cites W3113099567 @default.
• W2409125979 cites W43770513 @default.
• W2409125979 cites W86385217 @default.
• W2409125979 cites W347594833 @default.
• W2409125979 doi "https://doi.org/10.1182/blood.v83.3.724.724" @default.
• W2409125979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7507731" @default.
• W2409125979 hasPublicationYear "1994" @default.
• W2409125979 type Work @default.
• W2409125979 sameAs 2409125979 @default.
• W2409125979 citedByCount "113" @default.
• W2409125979 countsByYear W24091259792012 @default.
• W2409125979 countsByYear W24091259792013 @default.
• W2409125979 countsByYear W24091259792014 @default.
• W2409125979 countsByYear W24091259792015 @default.
• W2409125979 countsByYear W24091259792016 @default.
• W2409125979 countsByYear W24091259792017 @default.
• W2409125979 countsByYear W24091259792018 @default.
• W2409125979 countsByYear W24091259792020 @default.
• W2409125979 crossrefType "journal-article" @default.
• W2409125979 hasAuthorship W2409125979A5058237113 @default.
• W2409125979 hasAuthorship W2409125979A5073964632 @default.
• W2409125979 hasBestOaLocation W24091259791 @default.
• W2409125979 hasConcept C109159458 @default.
• W2409125979 hasConcept C114851261 @default.
• W2409125979 hasConcept C133936738 @default.
• W2409125979 hasConcept C137061746 @default.
• W2409125979 hasConcept C153911025 @default.
• W2409125979 hasConcept C202751555 @default.
• W2409125979 hasConcept C203014093 @default.
• W2409125979 hasConcept C2776364478 @default.
• W2409125979 hasConcept C2778707650 @default.
• W2409125979 hasConcept C2780007613 @default.

• next